Published in Medical Verdicts and Law Weekly, August 23rd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Merck KGaA.
Report 1: This year's American Society of Clinical Oncology (ASCO) meeting in Chicago sees a wealth of promising new data presented regarding Merck KGaA's targeted cancer therapy Erbitux(R) (cetuximab), further demonstrating the consistent efficacy and versatility of this agent in both first-line and subsequent treatment of metastatic colorectal cancer (mCRC) and squamous cell carcinoma of the head and neck (SCCHN).
Two new studies presented at the meeting validate the role...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.